The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

Inclusion Criteria: * Healthy Male volunteers * Body Mass Index between 19 and 29 Exclusion Criteria: * Subjects who received any prescribed medication within 5 half lives or 14 days of the first dose administration whichever is the longer * Subjects who have received any prescribed CNS medication or any medication known to chronically alter drug absorption or elimination processes within 30 days of first dose administration * Participation in a clinical trial of an investigational drug within the past 4 months or of a marketed drug within the past 3 months * History of allergy to NMDA antagonists or other clinically significant drug allergy * Supine blood pressure and heart rate of higher than 140/90 mmHg and 90 bpm respectively or lower than 80/40 mmHg and 40 bpm * Consumption of more than 21 units of alcohol per week or history of alcoholism or drug/chemical abuse * Smokers of more than 5 cigarettes or equivalent per day * Subjects who cannot complete the neuropsychological test battery * Any clinically significant health deficit